Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generics Liability Bill Could Face Uphill Road In Senate

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Leahy plans to introduce legislation to overturn the Supreme Court’s ruling in Pliva v. Mensing; the attorney who represented generic manufacturers in that case says the legislation is unlikely to pass.

You may also be interested in...



Supreme Court To Reconsider “Rules Of the Road” In Generic Preemption

Design defect claims made against generic companies are focus of a case involving Mutual Pharmaceutical’s generic sulindac; ruling may eliminate lower court carve-outs to its Mensing decision.

Generic Drug Liability: Harvard Researchers Propose New Adverse Events Database, Compensation Fund

Jerry Avorn and his colleagues suggest that a new database be created at FDA to be managed by the agency’s Sentinel program, PCORI or another organization; they also recommend development of a “consensus label” and a minimum Rx fee to fund pharmacovigilance.

Will Withdrawal Of Generic Bupropion XL Resurrect Product Liability Litigation?

Personal injury firms began looking for clients after FDA announced that Impax/Teva’s generic product was not equivalent to GSK’s Wellbutrin XL, but Supreme Court’s Mensing decision may keep cases from getting off the ground.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel